Skip to main content
Clinical Trials/NCT03335878
NCT03335878CompletedNot Applicable

Early Predictors of Brain Health and Development in Youth With T1DM

Washington University School of Medicine1 site in 1 country290 target enrollmentStarted: September 1, 2016Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
290
Locations
1
Primary Endpoint
Scaled score on Verbal IQ tests at 18 months

Study Overview

Brief Summary

Type 1 diabetes mellitus (T1DM) is typically diagnosed in childhood and over time can lead to complications affecting the retina, heart, kidneys, peripheral nerves, and more recently appreciated, the brain. Studies consistently find that early age of onset and, to a more variable extent, poor glycemic control over years are associated with reduced cognitive performance and altered brain structure in children with T1DM. As yet, the investigators' understanding of why early age of onset would pose more risks for the brain is limited, making interventions difficult to develop. Given that the initial clinical presentation of T1DM in children is the earliest and often the most severe glycemic state experienced over the lifetime, it is possible that age of onset and severity of initial clinical presentation interact to modify risks for brain health and development. This hypothesis has clear clinical implications and the potential to resolve conflicting literature, yet has not been explicitly tested. Thus, the goal of this study is to determine how clinical features at the time of T1DM diagnosis, such as hyperglycemia, diabetic ketoacidosis (DKA) and degree of beta cell failure, interact with age of onset to shape the development of the brain and its responses to subsequent glycemic control.

Detailed Description

NewT study staff will work with inpatient diabetes nurses and clinical diabetes educators at St. Louis Children's Hospital to identify patients that are admitted for new onset T1DM. Once the patients are clinically stable, the diabetes educator will visit the patient in the inpatient room and invite the family to participate in the study. If study participants would like to be enrolled, consent and assent will be obtained at that time. If potential participants are unsure at that time, the diabetes educator will provide the family with a blank copy of the consent form to be reviewed. Study information as well as contact information for study staff so that the family may contact the study should the family have additional questions or choose to enroll in the study. Following is a description of the testing days.

Mixed Meal Tolerance Tests (MMTTs) Once the patient has been consented to participate in the study, in the T1DM group, a Mixed-Meal Tolerance Tests (MMTT) will be administered at both study visits (3 mo & 21 mo post diagnosis). If participants are in the control group, the MMTT will only be administered at the 21 mo visit (18 months after the initial visit). For the MMTT, the T1DM group will be instructed to consume at least 150 g of carbohydrates per day for 3 days prior to the MMTT and to consume only water after midnight on the night prior to testing. If the patient is on insulin injection therapy the study nurse will ask the patient to administer the usual basal insulin dose(s) on the night before or on the morning of the study but to hold the morning dose of short- and intermediate-acting insulin. If the patient is on a continuous subcutaneous insulin pump infusions will remain on the usual basal rates for the duration of the study. For the MMTT a small needle, will be placed to collect blood samples. While there are multiple collection times, there is only one stick. The study nurse will then ask participants to drink a Boost High Protein Nutritional Energy Drink. Blood samples will then be obtained at the following time points: -10, 0, 15, 30, 60, 90, 120, 150, 180, 210, and 240 min. This amounts to approximately 4.5 tablespoons of blood. To clarify, only the T1DM group will have the MMTT at the first study visit (3 mo after T1DM dx), both the T1DM and the Control groups will have MMTT at the 21 month visit.

Cognitive Testing The cognitive testing or thinking tests, consist of memory tests, computer games and vocabulary tests. These tests will be administered by a trained staff member and will take approximately 60 minutes to complete. Some of the tests are: a Picture Vocabulary Test, a Picture Sequence Memory Test; an Inhibitory Control and Attention Test; a Dimensional Change Card Sort Test, and a List Sorting Working Memory Test.

Before and after the cognitive testing, blood glucose levels will be determined (using a finger prick) for participants in both groups. Participants with blood glucose values below 70 mg/dl or above 300 mg/dl will be treated and re-tested before testing resumes.

At some point during the study, one parent from each family will be requested to perform a brief reading test that provides an estimated intelligence quotient (IQ). This test takes approximately 10 minutes.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
4 Years to 16 Years (Child)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Otherwise healthy children with T1DM
  • Between the ages of 4 to 16 years old
  • Must be able to lie still in the MRI for 60 minutes

Exclusion Criteria

  • Mental retardation
  • Enrollment in special education classes or receiving special services
  • Major psychiatric (e.g. depression, autism) or neurological illnesses (e.g. head injury with loss of consciousness)
  • Currently taking medications with known central nervous system effects (including those for ADHD)
  • Physical limitations that would interfere with testing
  • Contraindications for MRI scans
  • Females who are pregnant and/or lactating will be excluded
  • Chronic diseases in addition to T1DM other than well-controlled asthma, celiac disease or Hashimoto's thyroiditis as determined by their clinical endocrinologist and/or nurse
  • Sibling Control Group
  • Inclusion Criteria:
  • Healthy sibling of a T1DM participant
  • Matched with a T1DM participant for age and gender
  • Between the ages of 4 to16 years old
  • Must be able to lie still in the MRI for 60 minutes
  • Exclusion Criteria
  • Mental retardation
  • Enrollment in special education classes or receiving special services
  • Major psychiatric (e.g. depression, autism) or neurological illnesses (e.g. head injury with loss of consciousness)
  • Currently taking medications with known central nervous system effects (including those for ADHD)
  • Physical limitations that would interfere with testing
  • Contraindications for MRI scans
  • Females who are pregnant and/or lactating will be excluded
  • Chronic diseases other than well-controlled asthma, celiac disease or Hashimoto's thyroiditis as determined by their clinical endocrinologist and/or nurse.
  • The Parent population will consist of one biological parent for each minor participant. The proxy participant will complete two neuropsychological tests as well as answer questionnaires about the minor study participant. The parent population has no age limitations but must be a biological parent to the minor study participant. The testing takes approximately 20 minutes thus the parent population will not be paid for their participation.

Outcomes

Primary Outcomes

Scaled score on Verbal IQ tests at 18 months

Time Frame: 18 months

The investigators hypothesize that age of onset and severity of presentation will interact to explain neuroimaging and cognitive outcomes at 3 months post-diagnosis. Specifically, the study investigators predict that patients with earlier age of onset and greater severity of clinical presentation (presence of DKA, greater HbA1c values at diagnosis) will have lower performance and more atypical brain structure and functional connectivity compared to older patients with less severe presentation and to age-matched controls, after controlling for gender, parental socioeconomic status (SES), parental IQ and intervening glycemic control. Primary neuroimaging outcomes are hippocampal volume and regional gray matter volume, microstructural white matter parameters and functional connectivity of the default mode network. Primary cognitive outcomes are memory and verbal intelligence.

Secondary Outcomes

  • White Matter Microstructure at 18 months(18 months)
  • Functional Connectivity of the Default Mode Network at 18 months(18 months)
  • Hippocampal Volume at 18 months(18 months)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials